Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.52 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.50 |
| ▸ | ESR1 | P03372 | 3/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.48 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5468498 | 0.88 | DYRK1A (0.54) | MAOADYRK1ACDK5CDK5R1ESR2 | |
| SCHEMBL5323077 | 0.82 | ALDH1A1 (0.56) | MAOAPIM1CSNK2A2CSNK2BPIM3 | |
| SCHEMBL18852012 | 0.82 | CSNK2B (0.51) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL18852011 | 0.82 | PIM1 (0.47) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL4072818 | 0.79 | MAOA (0.56) | MAOAPIM1CSNK2A2CSNK2BPIM3 | |
| SCHEMBL29640031 | 0.76 | CDK5 (0.55) | MAOADYRK1ACDK5CDK5R1GAA | |
| SCHEMBL14028590 | 0.73 | ALDH1A1 (0.47) | PIM1CSNK2A2CSNK2BPIM3PIM2 | |
| SCHEMBL5470345 | 0.70 | RAB9A (0.58) | MAOAPIM1CSNK2A2CSNK2BPIM3 | |
| SCHEMBL25703812 | 0.70 | ERCC5 (0.47) | MAOAKDM4EALDH1A1LMNAGLA | |
| SCHEMBL5027738 | 0.70 | CDK5 (0.62) | MAOADYRK1ACDK5CDK5R1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2033645-A1 | Isoquinoline derivatives and methods of use thereof | Inotek Pharmaceuticals Corporation (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20070249653-A1 | Tetracyclic benzamide derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249653-A1 | Tetracyclic benzamide derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| WO-2007117289-A2 | METHODS FOR TREATING OR PREVENTING ERECTILE DYSFUNCTION OR URINARY INCONTINENCE | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-10-18 | — | — | WO | disclosed |
| US-7217709-B2 | Tetracyclic benzamide derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-05-15 | — | — | US | disclosed |
| US-20060019980-A1 | Methods for treating or preventing erectile dysfunction or urinary incontinence | INOTEK PHARMACEUTICAL, CORP. (US) | 2006-01-26 | — | — | US | disclosed |
| US-6956035-B2 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-10-18 | — | — | US | disclosed |
| US-20050228007-A1 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2005-10-13 | — | — | US | disclosed |
| US-20040039009-A1 | Isoquinoline derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228007-A1 | Isoquinoline derivatives and methods of use thereof | GLS, PINK1, PARK7 | MAOA 1092/4885DYRK1A 1504/4885CDK5 799/4885 |
| US-20060019980-A1 | Methods for treating or preventing erectile dysfunction or urinary incontinence | PDE3A, PDE3B, PDE5A | MAOA 48/4885DYRK1A 4017/4885CDK5 2326/4885 |
| US-20040039009-A1 | Isoquinoline derivatives and methods of use thereof | CYP3A7, CYP3A5, ABCG2 | MAOA 485/4885DYRK1A 2348/4885CDK5 635/4885 |
| US-20070249653-A1 | Tetracyclic benzamide derivatives and methods of use thereof | TBC1D5, TBC1D15, BAD | MAOA 1772/4885DYRK1A 2528/4885CDK5 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.